Product imageResearch use only

CAT. NO. DC60212Featured

NT1-O14B

Research highlights

Tryptamine-derived lipidoidBioreducible disulfide tailsTau-ASO brain deliverySystemic Cre-protein delivery

Pack size & price

USD

Total$280

We match the best price and quality on market.

Ships from ShanghaiIce-pack transportPure lipid recommended

Product overview

Description & Application

NT1-O14B is a tryptamine-containing cationic lipidoid.1 It has been used in combination with other lipids in the formation of lipid nanoparticles (LNPs). Intravenous administration of LNPs containing NT1-O14B and encapsulating antisense nucleotides against tau decreases tau brain levels in mice.

CAS No.	2739805-64-0
Chemical Name	NT1-O14B
Synonyms	NT1O14B， NT1 O14B
SMILES	O=C(OCCSSCCCCCCCCCC)CCN(CCC1=CNC2=C1C=CC=C2)CCC(OCCSSCCCCCCCCCC)=O
Formula	C40H68N2O4S4
M.Wt	769.23
Purity	>95% by ELSD-HPLC
Storage	Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light.
Shipping condition	Ships from Shanghai. Pure lipid is stable during ice-pack transport.
Publication	Ma F, Yang L, Sun Z, et al. Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection. Science Advances. 2020;6:eabb4429.

Literature-reported formulation composition

Component	Reported mass ratio (w/w)	Role
NT1-O14B	3	Ionizable lipid
306-O12B-3	7	Additional lipid components
DSPE-PEG2000 (1 part per 24 parts mixed synthetic lipids)	1:24	PEG lipid
Reported ratio sum	Not reported	Original ratio retained

Formulation calculator unavailable. The source reports nested mass ratios and an average-mass PEG material, not a complete molar composition. No molar component-weight calculation is applied. Obtain and verify the complete composition and component molecular weights before planning component quantities.

N/P ratioNot reported in the cited article

Cargo:total lipids weight ratioTau-ASO:total lipids = 1:15 w/w

Buffer & pH25 mM sodium acetate, pH 5.2; final dialysis against deionized water.

CargoChemically modified Tau antisense oligonucleotide

Administration routeIntravenous tail-vein injection

Dose1 mg/kg Tau-ASO on days 0, 4, 8, 12 and 16

Animal modelC57BL/6J nontransgenic mice; n=6 per group in Fig.3C

Formulation processNT1-O14B and 306-O12B-3 were dissolved together in ethanol at the stated mass ratio, added dropwise to 25 mM sodium acetate buffer at 1:3 organic:aqueous volume ratio, vortexed, and dialyzed against deionized water for 12 h (35 kDa MWCO). For in vivo use, DSPE-PEG2000 was mixed with the synthetic lipids at 1:24 w/w. Tau-ASO was then mixed with total lipids at 1:15 w/w for 15 min at room temperature.

Literature-reported performance for the cited formulation

Literature-reportedBrain tau mRNA reductionApproximately 50%NT1-O14B/306-O12B-3 = 3:7 w/w; Tau-ASO:total lipids = 1:15 w/w; 1 mg/kg IV ×5 · Brain collected on day 20 · Pure NT1-O14B, pure 306-O12B-3, saline and scrambled ASO controls did not show the same reductionMain Results and Fig.3C

Literature-reportedBrain total tau protein reductionApproximately 30%NT1-O14B/306-O12B-3 = 3:7 w/w; same Tau-ASO regimen · Day 20 · Saline and scrambled Tau-ASOMain Discussion and Fig.3D

Estimated from figureASO-loaded particle characterizationAbout 175 nm, PDI about 0.18 and zeta potential about -16 mVNT1-O14B/306-O12B-3 = 3:7 w/w with ASOApproximate readings from plotted bars; the supplement does not print a numeric table.Supplementary Fig.S10A-B, pp.14-15

Additional reported findings

Cre-protein formulation

NT1-O14B/PBA-Q76-O16B = 3:7 w/w was mixed with (-27)GFP-Cre at protein:lipids = 1:4 w/w for 15 min. Four 50-microgram IV injections on days 0, 5, 10 and 15 produced tdTomato-positive cells in cerebral cortex, hippocampus and cerebellum; pure-lipid controls did not.

Ai14 mice, n=3 per group; brain collected day 20 · Main Fig.4 and Methods: In vivo delivery of GFP-Cre protein

Cre-loaded particle characterization

Supplementary Fig.S10 shows approximately 142 nm diameter, PDI approximately 0.24 and zeta potential approximately +15 mV for the loaded 3:7 NT1-O14B/PBA-Q76-O16B formulation.

Approximate values read from plotted bars; not a numeric table · Supplementary Fig.S10A-B, pp.14-15

Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.

The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.

Cited literature for this formulation and performance datasetMa F, Yang L, Sun Z, et al. Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection. Science Advances. 2020;6:eabb4429. DOI: 10.1126/sciadv.abb4429
Tau-ASO and Cre-protein results are shown as two distinct NT1-O14B mixed formulations. Pure NT1-O14B controls did not reproduce the reported intracellular effects.

Primary article

Laboratory planning

Solution Calculators

The product molecular weight is prefilled when available and remains editable. Confirm solvent compatibility and solubility before preparation.

Do not convert the reported 3:7, 1:24, 1:15 or 1:4 weight ratios to mol% or N/P.

Mass = concentration × volume × molecular weight

MassConcentrationVolumeMolecular weightg/mol

Enter any three values to calculate the fourth.

C₁V₁ = C₂V₂

C₁mMV₁mLC₂mMV₂mL

Enter any three values to calculate the fourth.

Preparing stock solutions

Quick preparation table

Solvent volumes update from the molecular weight above.

Mass	1 mM	5 mM	10 mM
10 mg	13.0000 mL	2.6000 mL	1.3000 mL
25 mg	32.5000 mL	6.5000 mL	3.2500 mL
50 mg	65.0001 mL	13.0000 mL	6.5000 mL
100 mg	130.0001 mL	26.0000 mL	13.0000 mL
250 mg	325.0003 mL	65.0001 mL	32.5000 mL

Need a different pack size or technical document?

Contact our team with the catalog number and requested quantity.

Handling guidance

Shipping, storage and sampling

How is the lipid shipped, and how should I store it?

We generally ship the neat (undissolved) lipid compound rather than an ethanol solution. The neat lipid is stable during transport with ice packs, and shipments originate from Shanghai. Pure form: store at −20 °C for up to 1 year. In solvent: store at −80 °C for up to 6 months or at −20 °C for up to 1 month. Keep sealed and protected from light. Avoid repeated thaw cycles for best results.

Pure lipid or solution — which should I choose?

Pure lipid is generally more stable during shipping and storage, so we usually recommend the pure form. A solution in ethanol or chloroform can be supplied when required by your workflow. Tell us the intended application, solvent and target concentration so the most suitable format can be confirmed.

How should I measure a small amount of oily or viscous lipid?

Ionizable lipids are often oily liquids or viscous semisolids, so material can be lost during repeated weighing or transfer. For a small pack, dissolve the entire quantity and aliquot it volumetrically. For example, add 1 mL ethanol to 25 mg lipid to prepare a 25 mg/mL stock, then use a pipette to withdraw the required amount. For quantities above 100 mg, direct weighing with an analytical balance may be more practical. Always confirm solvent compatibility and solubility first.

Can you support formulation optimization and scale-up?

Yes. Share the RNA cargo, target tissue, administration route, formulation method and assay plan. Our team can discuss starting molar ratios, N/P ratio and scale-up requirements for research workflows.

NT1-O14B

Pack size & price

Description & Application

Recommended Products

NT1-O12B

Lipid F10T5

C14-306

Lipid P3B

Lilly lipid 51

Lipid MK16

Lipid TD5

Lipid S4

DEA‑14‑DAP

Lipid CA2d